

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
4 April 2002 (04.04.2002)


PCT

(10) International Publication Number  
WO 02/26215 A2

- (51) International Patent Classification: A61K 9/51 (2006.01), C08L 67/02 (2006.01)
- (21) International Application Number: PCT/US01/30322
- (22) International Filing Date: 27 September 2001 (27.09.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/236,976 28 September 2000 (28.09.2000) US  
09/833,460 11 April 2001 (11.04.2001) US
- (71) Applicant: BATTELLE MEMORIAL INSTITUTE [US/US], Pacific Northwest Division, Intellectual Property Services, P.O. Box 999, Richland, WA 99352 (US).
- (72) Inventors: JEONG, Byeong, Moon, 2651 Sandstone Lane, Richland, WA 99352 (US); GUTOWSKA, Anna, 450 Mateo Court, Richland, WA 99352 (US)
- (74) Agent: MAY, Stephen, R., Battelle Memorial Institute, Pacific Northwest Division, Intellectual Property Services, P.O. Box 999, MSIN K1-53, Richland, WA 99352 (US)
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

[Continued on next page]

(54) Title: THERMOGELLING BIODEGRADABLE AQUEOUS POLYMER SOLUTION



(57) Abstract: Disclosed is a thermogelling biodegradable aqueous polymer solution useful in providing a bioactive agent delivery system. The present invention provides a thermogelling biodegradable aqueous polymer solution with a polyethylene glycol (PEG) block and a biodegradable polyester block, where the blocks are linked to form a polymer of a general structure comprising the formula of  $A_n(B)_m$ , where  $n$  is greater than 2 and  $A$  is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block,  $B$  is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block, and  $A$  is different from  $B$ .

WO 02/26215 A2



EE, EE, MC, NE, PL, SE, TR) OAPI patent (BL, BE, CH, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

*For two letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette*

**Published:**

*without international search report and to be republished upon receipt of that report*

## THERMOGELLING BIODEGRADABLE AQUEOUS POLYMER SOLUTION

### FIELD OF THE INVENTION

The present invention relates to a thermogelling biodegradable aqueous polymer solution composition and methods of use of such polymers for providing *in situ* forming, biodegradable implants.

### BACKGROUND OF THE INVENTION

Materials that gel *in situ* have recently gained attention as promising implantable drug delivery systems as well as injectable matrices for tissue engineering. There is an emerging need for materials that are biocompatible, promote cellular proliferation and biosynthesis, support physiological loads, and are easily manipulated and synthesized. Materials that gel *in situ* are promising as they are easily handled and permit cell seeding, they offer the ability to form any desired implant shape, and may be engineered to be biodegradable and biocompatible.

*In situ* gelation is the bases of injectable systems that eliminate the need for surgical procedures and offers the advantage of the ability to form any desired implant shape. The change in molecular association can be driven by changes in temperature, pH, or solvent composition. Among the candidates of stimuli sensitive systems, organic solvent-free injectable systems are designed by using the thermosensitive sol-to-gel transition of aqueous solution. Such a system enables bioactive agents to be easily entrapped.

To perform as an ideal injectable system, the aqueous solution of a polymer should exhibit low viscosity at formulation conditions and gel quickly at physiological conditions. Considering the biomedical applications, the biocompatibility of the polymers is also an important issue. Therefore, the material should be biodegradable, and by keeping

water rich hydrogel properties it should not induce tissue irritation during the degradation.

*In situ* gelling of aqueous Poloxamer 407 and N-isopropylacrylamide copolymers have been studied as candidate materials for injectable drug delivery systems and also tissue engineering applications. These materials are, however, non-biodegradable and animal studies demonstrated an increase in triglyceride and cholesterol after intraperitoneal injection of the aqueous Poloxamer 407 solution.<sup>9</sup>

Recently, Jeong et al. reported biodegradable, *in situ* gelling poly(ethylene glycol-b-(DL-lactic acid-co-glycolic acid)-b-ethylene glycol), (PEG-PLGA-PEG), triblock copolymers. (See US patent 6,117,949) They exhibited promising properties as an injectable drug delivery system. *In vivo* studies in rats demonstrated that the copolymer gels were still present after one month. During the degradation, the initially transparent gel became opaque due to preferential mass-loss of hydrophilic PEG rich segments. This change in morphology and the generation of an interface or phase might denature the protein drugs or cause cell deterioration in tissue engineering. *In vitro* release of porcine growth hormone (PGH) and insulin from the *in-situ* formed gel stopped after releasing 40-50 % of loaded proteins.

Recently, several protein/peptide drugs demonstrated excellent efficacy in clinical trials and have been introduced to the market. With the advent of genetic engineering, proteins/peptides will soon become much more common drugs. However, due to the short plasma half-life and instability of proteins, there are urgent needs for suitable delivery vehicles. Certain drug formulations need a one to two-week delivery system. Moreover, a one to two-day delivery system may be required. For example, ifosfamide, a drug used for germ cell testicular cancer, is administered intravenously for 5 consecutive days. This treatment is repeated every three weeks or after recovery from hematological toxicity. In order to prepare such a short-term delivery system, poly(ethylene glycol) grafted with poly(lactic acid-co-glycolic acid) (PEG-g-PLGA), where

hydrophilic PEG is a backbone, is designed. This material is expected to show a different gelation and degradation behavior, and consequently, a different drug release profile as compared to PEG-PLGA-PEG.

The following references disclose processes or compounds useful

5 in this art:

U.S. Patent No. 5,702,717

U.S. Patent No. 5,117,949

Hill-West, J. L.; Chowdhury, S. M.; Slepian, M. J.; Hubbell, J. A. *Proc. Natl. Acad. Sci. USA*, **1994**, 91, 5967-5971.

10 Stile, R. A.; Burghardt, W. R.; Healy, K. E. *Macromolecules*, **1999**, 32, 7370-7379.

Chen, G. H.; Hoffman, A. S.; *Nature*, **1995**, 373, 49-52.

Thomas, J. L.; You, H.; Tirrell, D. *J. Am. Chem. Soc.*, **1995**, 117, 2949-2950.

15 Malstom, M.; Lindman, B. *Macromolecules*, **1992**, 25, 5446-5450.

Yang, J.; Pickard, S.; Deng, N. J.; Barlow, R. J.; Attwood, D.; Booth, C. *Macromolecules*, **1994**, 27, 670-680.

Jeong, B.; Bae, Y. H.; Lee, D. S.; Kim, S. W. *Nature*, **1997**, 388, 860-862.

20 Johnston, T. P.; Punjabi, M. A.; Froelich, C. J. *Pharm. Res.*, **1992**, 9(3), 425-434.

Wout, Z. G. M.; Pec, E. A.; Maggiore, J. A.; Williams, R. H.; Palicharla, P.; Johnston, T. P. *J. Parenteral Sci. & Tech.*, 1992, 46(6), 192-200.

Jeong, B.; Bae, Y. H.; Kim, S. W. *J. Controlled Releases*, **2000**, 63, 155-163.

25 Jeong, B.; Bae, Y. H.; Kim, S. W. *J. Biomed. Mater. Res*, **2000**, 50 (2), 171-177.

Jeong, B.; Gutowska, A. *J. Am. Chem. Soc.*, **2000**. Submitted.

Jeong, B. Unpublished Data. **2000**.

IFEX Prescription, <http://www.ifex.com/ifpre.html>, A Bristol-Meyers

30 Squibb Co., Princeton, NJ 08543

Bellare, J. R.; Davis, H. T.; Scriven, L. E.; Talmon, Y. *J. Electron Microsc. Tech.* **1988**, 10, 87-111.

- Wanka, G.; Hoffmann, H.; Ulbricht, W. *Colloid Polym. Sci.*, **1990**, 268, 101-117.
- Tanodekaew, S.; Godward, J.; Heatley, F.; Booth, C. *Macromol. Chem. Phys.*, **1997**, 198, 3385-3395.
- 5 Odian, G. In *Principles of Polymerization*, 2<sup>nd</sup> ed.; John Wiley & Sons, Inc. Korean Student Ed.: Korea, 1981; p513.
- Alexandrisdis, P.; Holzwarth, J. F.; Hatton, T. A. *Macromolecules*, **1994**, 27, 2414-2425.
- Discher, B. M.; Won, Y.-Y.; Ege, D. S.; Lee, J. C. M.; Bates, F. S.;
- 10 Discher, D. E.; Hammer, D. A. *Science*, **1999**, 284, 1143-1146.
- Won, Y.-Y.; Davis, H. T.; Bates, F. S. *Science*, **1999**, 283, 960-963.
- Brown, W.; Schillen, K.; Almgren, M.; Hvidt, S.; Bahadur, P. *J. Phys. Chem.*, **1991**, 95, 1850-1858.
- Cau F.; Lacelle, S. *Macromolecules*, **1996**, 29, 170-178.
- 15 Jeong, B.; Bae, Y. H.; Kim, S. W. *Colloids and Surfaces B: Biointerfaces*, **1999**, 16: 185-193.
- Zhou, Z.; Chu, B. *J. colloid and Interface Science*, **1988**, 126(1): 171-180.
- Deng, Y.; Yu, G. E.; Price, C.; Booth, C. *J. Chem. Soc. Faraday Trans.* **1992**, 88(10), 1441-1446.
- 20 Yu, G. E.; Deng, Y.; Dalton, S.; Wang, Q. G.; Attwood, D.; Price, C.; Booth, C. *J. Chem. Soc., Faraday Trans.* **1992**, 88 (17), 2537-2544.
- Jeong, B.; Bae, Y. H.; Kim, S. W. *Macromolecules* **1999**, 32, 7064-7069.
- Israelachvili, J. N. *Intermolecular and Surface Forces*, Academic Press, New York, 1985.
- 25 Feil, H.; Bae, Y. H.; Feijen, J.; Kim, S. W. *Macromolecules*, **1993**, 26, 2496-2500.
- Jeong, B.; Lee, D. S.; Shon, J. I.; Bae, Y. H.; Kim, S. W. *J. Polym. Sci. Polym. Chem.* **1999**, 37, 751-760.

## SUMMARY OF THE INVENTION

5 The present invention provides a thermogelling biodegradable aqueous polymer solution with a polyethylene glycol (PEG) block and a biodegradable polyester block, where the blocks are linked to form a polymer of a general structure comprising the formula of  $A_n(B)$ , where n  
10 is greater than 2 and A is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block, B is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block, and A is different from B.

15 It is an object of the present invention to provide a thermogelling biodegradable polymer solution having utility as a bioactive agent delivery system.

A further object of this invention is to provide a drug delivery system that can be injected parenterally.

20 Another object of this invention is to provide a drug delivery system that allows control of polymer degradation rate or duration of a sustained gel by controlling the number of branches linked to the backbone of the structure or by mixing a first polymer comprising the formula  $A_n(B)$  with at least one other polymer comprising the formula  $A_n(B)$ , wherein the first polymer is different from said at least one other  
25 polymer.

Still another object of this invention is to provide a drug delivery system that allows control of the stability of drugs and drug dosage from one day to two months.

30 Another object of this invention is to provide block copolymer drug delivery systems that are biodegradable.

Still another object of this invention is to provide block copolymer drug delivery systems that demonstrate desirable release rates.

Another object of this invention is to provide injectable block copolymer drug delivery systems that are in solution at room temperature or lower and gel at or about physiological temperature.

Yet another object of this invention is to provide injectable drug  
5 delivery systems that eliminate the need for surgical procedures and offers the advantage of the ability to form any desired implant shape.

Still another object of this invention is to provide stimuli sensitive, organic solvent-free injectable drug delivery systems that are designed by using the thermosensitive sol-to-gel transition of aqueous solutions.

10 Yet another object of this invention is to provide an aqueous solution of a polymer that exhibits low viscosity at formulation conditions and gels quickly at physiological conditions.

Still yet another object of this invention is to provide drug delivery systems that can provide desired release rates by varying the ratio of  
15 polyethylene glycol (PEG) block and a biodegradable polyester block.

Additional objects and advantages of this invention will become apparent from the following summary and detailed description of the various embodiments making up this invention.

There is an emerging need for materials that are biocompatible,  
20 promote cellular proliferation and biosynthesis, support physiological loads, and are easily manipulated and synthesized. Materials that gel in situ are promising as they are easily handled, permit cell seeding, and they offer the ability to form any desired implant shape. The present invention is well suited for delivery of cells, whereby the thermogelling  
25 biodegradable aqueous polymer solution provides a scaffold for tissue repair and organ regeneration. The present invention offers several advantages including: the flowability of the thermogelling biodegradable aqueous polymer solutions can fill any shape of a defect, promotion of tissue integration, easily incorporates live cells and various therapeutic  
30 agents (e.g. growth factors), and finally enables minimally invasive placement.



Therefore, another object of this invention is to provide a thermogelling biodegradable polymer solution having utility in tissue engineering.

Still another object of this invention is to provide a thermogelling biodegradable polymer solution having utility as a cell delivery system.

Yet still another object of this invention is to prepare biodegradable solubilizers for hydrophobic drugs. Due to surfactant nature of the PEG-g-PLGA and PLGA-g-PEG, this polymer can be used as a solubilizer for hydrophobic drug formulations.

For a clear and concise understanding of the specification and claims, including the scope given to such terms, the following definitions are provided:

**Bioactive Agent:** As used herein, a "bioactive agent" shall mean any drug, molecule, biomolecule, or cell.

**Drug:** As used herein, a "drug" shall mean any organic compound or substance having bioactivity and adapted or used for a therapeutic purpose.

**Polypeptide:** As used herein, a "polypeptide" shall mean any peptide, polypeptide, oligopeptide, and/or protein used as a drug and shall not be limited by molecular weight, sequence, length, activity or use.

**Parenteral:** Administering into the body or administered in a manner other than through the digestive tract, as by intravenous or intramuscular injection.

## BRIEF DESCRIPTION OF THE DRAWINGS

A more complete appreciation of the invention will be readily obtained by reference to the following description and the accompanying drawings in which like numerals in different figures represent the same structures or elements, wherein:

**Figure 1** is a schematic representation of the synthesis of PEG-g-PLGA.

**Figure 2** is a graphical representation of NMR spectra of intermediate and final products of PEG-g-PLGA synthesis.

5        **Figure 3** is graphical representation of a GPC chromatogram of polymers showing progress of reactions.

**Figure 4** is a Cryo-TEM image showing micelle formation of the PEG-g-PLGA polymer at a concentration of 1 wt% in water at 23.7° C.

10       **Figure 5a** is a graphical representation of UV spectra showing the formation of core-shell structure of polymers in water at 20° C where DPH concentration was fixed at 4  $\mu$ M and polymer concentration varied according to key legend.

**Figure 5b** is a graphical representation of the cmc determination by extrapolation of the difference in absorbance at 377 and 392 nm.

15       **Figure 6** is a graphical representation of real part ( $n'$ ) of complex viscosity and elastic modulus ( $G'$ ) of 22 wt% PEG-g-PLGA aqueous solutions as a function of temperature.

**Figure 7** is a graphical representation of a phase diagram of PEG-g-PLGA aqueous solution.

20       **Figure 8** is a graphical representation of the calculation of enthalpy of sol-to-gel transition of PEG-g-PLGA aqueous solutions.

**Figure 9** is a graphical representation of the  $^{13}\text{C}$ -NMR spectra of PEG-g-PLGA in  $\text{D}_2\text{O}$  (22 wt. %) as a function of temperature.

25       **Figure 10** is a graphical representation of the storage modulus of PLGA-g-PEG as a function of temperature and concentration.

**Figure 11a** is a graphical representation of a rheological study of PLGA-g-PEG copolymer aqueous solutions (25 wt.%) wherein the real part ( $\eta'$ ) of complex viscosity of the copolymer solution was measured as a function of temperature.

30       **Figure 11b** is a graphical representation of a rheological study of PLGA-g-PEG copolymer aqueous solutions (25 wt.%) wherein the storage

modulus (G) of the copolymer solution was measured as a function of temperature.

**Figure 12** is a graphical representation of a  $^{13}\text{C}$ -NMR (75MHz) spectra of 25% (wt.) PLGA-g-PEG copolymer in  $\text{D}_2\text{O}$  as a function of temperature wherein the zoom spectra ( $\sim 73$  ppm) are shown at left.

**Figure 13** is a graphical representation of a deuterium NMR showing reversibility of the sol-gel transition.

## DETAILED DESCRIPTION

The present invention is a biodegradable polymer solution, comprising a polyethylene glycol (PEG) block, and a biodegradable polyester block linked to form a polymer of a general structure comprising the formula of  $A_n(B)$ , where  $n$  is greater than 2 and  $A$  is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block,  $B$  is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block, and  $A$  is different from  $B$ .

The present invention further provides a thermogelling biodegradable aqueous polymer solution which comprises a biodegradable polymer solution, comprising a polyethylene glycol (PEG) block, and a biodegradable polyester block linked to form a polymer of a general structure comprising the formula of  $A_n(B)$ , where  $n$  is greater than 2 and  $A$  is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block,  $B$  is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block, and  $A$  is different from  $B$ , and an aqueous solution.

The thermogelling biodegradable aqueous polymer solution is preferred when prepared with the formula  $A_n(B)$  as described previously and  $n$  is between 3 and 10.

The biodegradable polyester block is preferably a member selected from the group consisting of poly(DL-lactic acid), poly(L-lactic acid), poly(glycolic acid), poly( $\epsilon$ -caprolactone), poly( $\gamma$ -butyrolactone), poly( $\alpha$ -valerolactone), poly( $\beta$ -hydroxybutyric acid), and their copolymers or  
5 terpolymers. It is also preferred that the copolymers and/or terpolymers are selected from the group consisting of poly(DL-lactic acid-co-glycolic acid), poly(L-lactic acid-co-glycolic acid), poly( $\epsilon$ -caprolactone-co-DL-lactic acid), copoly( $\epsilon$ -caprolactone-co-DL-lactic acid-glycolic acid). The above listing of suggested biodegradable polyester blocks is not intended  
10 to be all-inclusive. The biodegradable polyester blocks can have a maximum molecular weight of 100,000 with a preferred range of about 1,000 and 30,000, and most preferably between about 1,000 and 10,000. The biodegradable polyester blocks are limited as a result of the desire to accommodate a solubility limit and not because of degradability

15 It is preferred that the polyethylene glycol (PEG) block have an average molecular weight of between about 300 and 20,000 and is more preferably between about 500 and 10,000. The PEG block with a higher molecular weight than 10,000 is hard to be filtered through glomeruli filtration.

20 The present invention provides an effective biodegradable bioactive agent delivery liquid, comprising an effective amount of bioactive agent contained in thermal gelling biodegradable aqueous polymer solution comprising a polyethylene glycol (PEG) block, and a biodegradable polyester block linked to form a polymer of a general structure  
25 comprising the formula of  $A_n(B)$ , where  $n$  is greater than 2 and  $A$  is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block,  $B$  is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block, and  $A$  is different from  $B$ .

30 It is understood that the present invention can make use of any bioactive agent, which can be any drug, molecule, biomolecule, or cell.

As well, the present invention can provide as a delivery system for other matter requiring a sustained release rate.

The thermogelling biodegradable aqueous polymer solutions of the present invention are useful as drug delivery systems that provide as a carrier for drugs. A drug is an organic compound or substance having bioactivity and adapted or used for a therapeutic purpose including but not limited to anti-cancer agents, hormones, antibiotics, narcotic antagonists, analgesics, anti-inflammatory agents, anti-depressants, anti-epileptics, anti-malarial agents, immunoactivators, growth factors, gene therapy agents, oligonucleotides, therapeutic peptides and proteins, and combinations thereof. In particular, the present invention provides a very useful delivery system for polypeptide and protein drugs that require a short biodegradation period to accommodate the requirement for a specific sustained release rate due to the short plasma half-life and instability.

Because the polymers of the present invention are composed of hydrophobic and hydrophilic blocks and the surfactant nature, this polymer can be used as a solubilizer for hydrophobic drug formulations. This property enables these polymers to be used as a solubilizer of hydrophobic drugs. Typical cancer drugs, such as Taxol, have good efficacy while they tend to have low solubility in water. The polymers of the present invention can be used as biocompatible solubilizers for such drugs.

The present invention is well suited for delivery of anti-cancer agents. It is preferred that the anti-cancer agents be selected from the group consisting of adriamycin, mitomycin, bleomycin, cisplatin, carboplatin, doxorubicin, daunorubicin, 5-fluorouracil, methotrexate, taxol, taxotere, and actinomycin D. It is understood that other anti-cancer agents may work as well with this invention and the preceding list is not meant to be all-inclusive.

The present invention is equally well suited for delivery of polypeptides. It is preferred that that polypeptides be selected from the

group consisting of oxytocin, vasopressin, adrenocorticotrophic growth factor (PDGF), prolactin, luteinising hormone releasing hormone (LHRH), growth hormone, growth hormone releasing factor, insulin, somatostatin, glucagons, interleukin-2 (IL-2), interferon- $\alpha, \beta, \gamma$  (IFN-  $\alpha, \beta, \gamma$ ), gastrin, tetragastrin, pentagastrin, urogastroine, secretin, 5 cacinonin, enkephalins, endorphins, angiotensins, thyrotropin releasing hormone (TRH), tumor necrosis factor (TNF), nerve growth factor (NGF), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (M-CSF), rennin, bradykinin, bacitracins, 10 polymixins, colistins, tyrocidin, gramicidines, and synthetic analogues, modifications and pharmacologically active fragments thereof, monoclonal antibodies and soluble vaccines. This list is not all-inclusive and it is understood that other proteins can be used as well.

The present invention is well suited for delivery of cells. The 15 thermogelling biodegradable aqueous polymer solution comprising cells provides a scaffold for tissue repair and organ regeneration as well as for therapeutic use.

A useful aspect of the present invention is method for the delivery of a bioactive agent in a thermogelling polymer matrix to a warm-blooded 20 animal for the controlled release of the bioactive agent. Fundamental to this aspect of the invention is to provide an injectable thermogelling biodegradable aqueous polymer solution which comprises a polyethylene glycol (PEG) block, a biodegradable polyester block, wherein the blocks are linked to form a polymer of a general structure comprising the 25 formula of  $A_n(B)$ , where  $n$  is greater than 2 and  $A$  is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block,  $B$  is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block, and  $A$  is different from  $B$ . The thermogelling biodegradable aqueous polymer solution is then 30 mixed with an effective amount of a bioactive agent to form a polymer-bioactive agent mixture, maintained at a temperature below the gelling temperature of the polymer, and provided into a warm blooded animal to

form a gel depot as the temperature is raised by the body temperature of the animal to be above the gelling temperature of the polymer. It is recognized that this aspect of the present invention can have various forms of application. For example, it is well suited to use this method of application when it is desired to apply a bioactive agent to a warm-blooded animal during a surgical procedure where a portion of the body of the warm-blooded animal is exposed. By applying the polymer-bioactive agent mixture to an area exposed during surgery will allow the formation of a depot to a specific/desired area.

Another aspect of the present invention is method for the parenteral delivery of a bioactive agent in a thermogelling polymer matrix to a warm-blooded animal for the controlled release of the bioactive agent. Fundamental to this aspect of the invention is to provide an injectable thermogelling biodegradable aqueous polymer solution which comprises a polyethylene glycol (PEG) block, a biodegradable polyester block, wherein the blocks are linked to form a polymer of a general structure comprising the formula of  $A_n(B)$ , where  $n$  is greater than 2 and  $A$  is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block,  $B$  is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block, and  $A$  is different from  $B$ . The injectable thermogelling biodegradable aqueous polymer solution is then mixed with an effective amount of a bioactive agent to form a polymer-bioactive agent mixture, maintained at a temperature below the gelling temperature of the polymer, and injected into a warm blooded animal to form a gel depot as the temperature is raised by the body temperature of the animal to be above the gelling temperature of the polymer. This aspect of the invention provides well when it is desired to provide a bioactive agent under controlled release without having to surgically expose a warm-blooded animal. Several injectable routes including intradermal or intracutaneous, subcutaneous or hypodermic, intramuscular, intravenous, and intraspinal can administer the polymer-bioactive agent mixture parenterally.

Having described the invention, the following experimental examples are given. These specific examples are not intended to limit the scope of the invention described in this application.

## Experimental Section:

### Materials:

DL-lactide (Polyscience) and glycolide (Polyscience) were recrystallized from ethyl acetate. Glutaric anhydride (Aldrich), glutaric acid (Aldrich), stannous octoate (Aldrich), epoxy terminated polyethylene glycol (m.w.: 600; Polyscience), poly(ethylene glycol m.w.: 1000; Aldrich), and 1,6-diphenyl-1,3,5-hexatriene (DPH; Aldrich) were used as received.

### Synthesis: three-step synthesis of PEG-g-PLGA (**Fig. 1.**)

First, PEGs (m.w. = 1000, 38.28 g, 38.28 mmole) were dissolved in 90 ml toluene. Toluene was then distilled off to a final volume of 50 ml to remove water by azeotropic distillation. Carboxylic acid terminated PEG (CPEG) was prepared by reacting PEG with excess amount of glutaric anhydride in the presence of catalytic amounts of glutaric acid. Glutaric anhydride (7.255 g, 80.39 mmole) and glutaric acid (0.042 g, 0.40 mmole) were added and the reaction mixture was stirred at 120 °C for 6 hours. The chemical shifts (ppm) in the spectra are 1.9 (central methylene of glutarate), 2.4 (methylene of glutarate next to carbonyl group), 3.6 (ethylene of PEG), and 4.2 (methylene of PEG connected to glutarate). The one to one area ratio of the peaks at 1.9 ppm and 4.2 ppm indicates the quantitative end group functionalization. Diethyl ether was added to the reaction mixture to precipitate out the carboxylic acid terminated PEG (CPEG). The product was placed under high vacuum ( $\sim 10^{-3}$  mm Hg) for 48 hours to remove the residual solvent.

In the second step, epoxy terminated PEG (EPEG) (m.w. = 600, 5.619 g, 9.36 mmole) was reacted with CPEG (11.50 g, 9.36 mmole) in toluene at 120 °C for 24 hours to prepare PEG with pendant hydroxyl groups (PEGH) along the PEG backbone. The weight average molecular



weight ( $M_w$ ) and polydispersity index (PDI) of resulting PEGH, which were determined by GPC, was 3000 and 1.3 relative to polystyrene standards. The peaks at 1.9 ppm and 2.4 ppm come from glutarate. The peaks at 3.6 ppm and 4.3 ppm come from PEG. The small overlapped peaks 3.4 to 4.2 ppm of PEGH come from the connecting methylene or methine moieties between CPEG and EPEG (**Fig. 2**).

In the third step, DL-lactide (19.2 g, 133.3 mmole) and glycolide (6.4 g, 55.1 mmole) were polymerized *in situ* on the preformed PEGH backbone at 130 °C for 24 hours, using stannous octoate (76  $\mu$ L, 0.187 mmole) as a catalyst. The graft copolymers were precipitated into excess ethyl ether and the residual solvent was removed under vacuum.

There are two possibilities of the ring-opening pattern of the epoxy group during the reaction of EPEG and CPEG. The nucleophiles prefer to attack the sterically less hindered side of the epoxy group in the base-catalyzed addition, while ring opening is less regiospecific in cationic polymerization. The GPC chromatogram in **Fig. 3** shows the increase in molecular weight by the formation of PEGH from CPEG and EPEG. Assuming a PEGH molecular weight of about 3,000, there are ~ 2 - 3 pendant hydroxy groups per each PEGH.

The resultant PEGH was used as an initiator for the ring-opening polymerization of DL-lactide and glycolide in the presence of stannous octoate as a catalyst.  $^1\text{H-NMR}$  spectra (**Fig. 2**) show an ethylene glycol unit at 3.6 ppm, a lactic acid unit at 5.3 ppm (methine) and 1.8 ppm (methyl), and a glycolic acid unit at 4.8 ppm. Composition of the PEG-g-PLGA calculated by  $^1\text{H-NMR}$  was 2.98/2.35/1.00 (ethylene glycol/DL-lactic acid/glycolic acid) in mole ratio. The methylene protons of the epoxy group show up at 2.6 ppm and 2.8 ppm in  $^1\text{H-NMR}$ . In the  $^1\text{H-NMR}$  spectrum of PEGH and PEG-g-PLGA the epoxy signals are too small to be analyzed quantitatively. Weight average molecular weight ( $M_w$ ) and PDI of PEG-g-PLGA determined by GPC relative to polystyrene standards was 11,000 and 1.3 respectively.

#### Gel Permeation Chromatography (GPC):

The GPC system (Waters 515) with a refractive Index Detector (Waters 410) and a Light Scattering Detector Mini Dawn (Wyatt Technology) were used to obtain molecular weight and molecular weight  
5 distribution. Styragel<sup>®</sup> HMW 6E and HR 4E columns (Waters) were used in series. Tetrahydrofuran (THF) was used as an eluting solvent.

#### Cryo-Transmission Electron Microscope (Cryo-TEM):

Using cryo-TEM, a 1% PEG-g-PLGA solution was investigated in  
10 the form of vitreous films. Detailed procedures for the sample preparation have been published elsewhere. (Bellare et. al., *Electron Microsc. Tech.* 1999, 10, 87-111.) The liquid films of 10 to 300 nm thickness freely spanning across the micropores in a carbon-coated  
15 lacelike polymer substrate were prepared at 23.7° C with complete control of temperature and humidity, and rapidly vitrified with liquid ethane at its melting temperature (-180° C). Imaging was performed using a JEOL 1210 operating at 120 kV. Adequate phase contrast was  
20 obtained at a nominal underfocus of ~ 6 micrometers. Images were recorded on a Gatan 724 multiscan camera, and optical density gradients in the background were digitally corrected.

#### CMC Determination:

Hydrophobic dye, 1,6-diphenyl-1,3,5-hexatriene (DPH) was dissolved in methanol with a concentration of 0.4 mM. This solution (20  
25  $\mu$ L) was injected using a microsyringe into 2.0 ml PEG-PLGA polymer aqueous solution with various concentrations between 0.0032 and 0.26 wt. % and equilibrated for 5 hours at 4° C. UV-VIS spectrometer (HP 8453) was used to get the UV-VIS spectra in the range of 280 to 450 nm at 20° C. CMC was determined by the plot of the difference in absorbance  
30 at 377 nm and at 391 nm ( $A_{377} - A_{391}$ ) versus logarithmic concentration.

Viscosity:

The viscosity of PEG-g-PLGA aqueous solution (22 wt. %) was measured as a function of temperature. A Canon-Fenske viscometer 200 with a viscometer constant of 0.0966 centistokes/sec. was used to measure the viscosity of the polymer solution.

Dynamic Mechanical Analysis:

The sol-gel transition of the graft copolymer aqueous solution (22 wt. %) was investigated using a dynamic mechanical rheometer (Rheometric Scientific: SR 2000). The polymer solution was placed between parallel plates having a diameter of 25 mm and a gap distance of 0.5 mm. The data were collected under controlled stress (4.0 dyne/cm<sup>2</sup>) and frequency of 1.0 radian/second. The heating and cooling rate was 0.2° C/min.

Sol-Gel Transition:

The sol-gel transition was determined by a test tube inverting method with a temperature increment of 1° C per step. Polymer aqueous solutions (0.5 g) were prepared in 4 mL vials with inner diameters of 11 mm. The vials were immersed in a water bath at each step for 15 minutes. The sol-gel transition temperature was monitored by inverting the vials, and if there was no flow in 30 seconds, it was regarded as a gel. The transition temperature was determined with ±1° C accuracy.

NMR Study:

A NMR spectrometer (Varian® VXR 300) was used for <sup>1</sup>H-NMR and <sup>13</sup>C-NMR to study composition and microenvironment change during sol-to-gel transition. For the <sup>13</sup>C-NMR in D<sub>2</sub>O, a 22 wt. % PEG-g-PLGA solution was prepared.

## Results and Discussion

### Micellization:

PEG-g-PLGA is an amphiphilic copolymer and a core-shell structure can be expected in water. The hydrophobic PLGA side chains form a core and the hydrophilic PEG backbones form a shell region. The formation of core-shell structure was investigated by Cryo-transmission electron microscopy (Cryo-TEM) and dye solubilization method.

The formation of micelles was directly confirmed by a Cryo-TEM image. An 1 wt. % PEG-g-PLGA solution at 23.7 °C was quenched into a vitrified form at -180 °C. The Cryo-TEM image shows closely packed spherical micelles (denoted as S in Figure 3) on the left side of black stripe. The diameter of a micelle is about 9 nm. (**Fig. 4**)

At a fixed concentration of DPH, the polymer concentration was increased from 0.0032 to 0.26 wt. %. The absorption coefficient of the hydrophobic dye (DPH) is much higher in a hydrophobic environment than in water. Thus, with increasing polymer concentration, the absorbance at 377 and 356 nm increased, indicating that the polymers formed a core-shell structure in water creating a hydrophobic environment (Figure 4-a). The critical micelle concentration (CMC) was determined by extrapolating the absorbance at 377 nm minus absorbance at 391 nm ( $A_{377} - A_{391}$ ) versus logarithmic concentration (Figure 4-b) to compensate for the scattering effect. The CMC value determined by this extrapolation is not precise due to the uncertainty in the line, but it is in a range of 0.01-0.05 wt. % at 20° C. **Fig. 5a** is a UV spectrum showing the formation of core-shell structure of polymers in water at 20° C. DPH concentration was fixed at 4μM and polymer concentration varied: 0.0032, 0.01, 0.0178, 0.032, 0.056, 0.10, 0.178, 0.26 wt.%. The increase in absorption band at 377 nm with increasing polymer concentration indicates the formation of a hydrophobic environment, that is, micelles, in water. **Fig. 5b** shows a CMC determination by extrapolation of the difference in absorbance at 377 nm and at 391 nm.

### Sol-Gel Transition:

At high concentrations, the PEG-g-PLGA aqueous solution undergoes a sol-to-gel transition with increasing temperature. The viscosity of a 22 wt. % PEG-g-PLGA aqueous solution that was measured by Cannon-Fenske viscometer was 27 centipoises at 20° C. This viscosity is low enough for an easy formulation of the polymer with pharmaceutical agents that could be injected using a 22-gauge needle. Above the gelation temperature, the viscosity is too high to flow through the capillary of this viscometer. Dynamic mechanical analysis of 22 wt. % aqueous polymer solutions show that the real part ( $\eta'$ ) of complex viscosity increases from 5 to 500 dyne sec cm<sup>-2</sup> [P] and elastic modulus ( $G'$ ) increased from zero to 100 dyne cm<sup>-2</sup> during a sol-to-gel transition (**Fig.6**).  $\eta'$  and  $G'$  are measures of dissipated energy and stored energy respectively when a material is subject to cyclic deformation. And, practically no flow was observed above 30° C in the test-tube inverting method, indicating a sol-to-gel transition. When we compare the two methods for 22 wt % aqueous polymer solutions, the gelation temperature determined by test-tube inverting method corresponds to the temperature at which  $\eta'$  of 100 P and  $G'$  of 50 dyne/cm<sup>2</sup> are reached in dynamic mechanical analysis when thermal equilibrium is assumed in both cases.

The phase diagram of PEG-g-PLGA aqueous solutions determined by a test-tube inverting method is shown in Figure 6. The sol-to-gel transition is accompanied by a sharp increase in viscosity. The critical gel concentration (CGC) above which the gel phase appears was about 16 wt. %. Below CGC, the system flows even though the viscosity increases as the temperature increases. The sol-to-gel transition temperature, estimated at about 30° C, was slightly affected by the polymer solution concentration. The presence of the gel phase around body temperature (37° C) indicates that the material is a promising candidate for an injectable drug delivery system that can be formulated at room

temperature, and would form a gel *in situ* upon subcutaneous or intramuscular injection. The pharmaceutical agents would then be slowly released from the *in situ* formed gel.

Further analysis of the phase diagram illustrates that with increasing temperature the gel exhibits syneresis, marked as gray triangles in **Fig. 7**, a macromolecular phase separation where some amount of water is exuded from the gel phase. Above the syneresis temperature, the gel phase remains separated from the water. Therefore, the sol phase at low temperature is a homogeneous one-phase solution while the sol phase above syneresis is a two-phase system. The gel region, right side of the trend line in the phase diagram indicates the area where a uniform gel phase exists. Based on the phase diagram (**Fig. 7**), 21-25 wt. % of PEG-g-PLGA aqueous solutions are recommended as injectable formulations for drug delivery.

The aggregation number of a micelle can be estimated from the size of the micelle by assuming that the micelle is a hard sphere. The radius of a micelle can be estimated from equation.

$$a. R = (3M_{s,D} \nu_2 / 4\pi N_A)^{1/3}$$

Where  $M_{s,D}$  denotes the molecular weight of a micelle obtained from centrifugal sedimentation, which is close to weight average molecular weight ( $M_w$ ).  $\nu_2$ , and  $N_A$  are the partial specific volume of the polymer, and the Avogadro's number, respectively. The aggregation number of a micelle ( $N_{ag}$ ) is given by equation.

$$b. N_{ag} = M/M_0$$

Where  $M$  and  $M_0$  denote molecular weight of a micelle and molecular weight of a polymer respectively. Assuming  $\nu_2$  is 0.95, which is typical for polyester or polyether, and  $R$  is about 4.5 nm (diameter ~ 9 nm) from Cryo-TEM, the micellar aggregation number is 40 at 20° C. The

aggregation number of a micelle is assumed to be practically constant for a sol region as in the cases of PEG-PLGA-PEG and poloxamer 407. This calculation also assumes that  $M$  is equal to  $M_{s,D}$  and the molecular weight of PEG-g-PLGA ( $M_0$ ) is 6000 as determined from GPC data. Based on this estimation, the thermodynamic functions such as enthalpy ( $\Delta H^0$ ), Gibbs free energy ( $\Delta G^0$ ), and entropy of gelation ( $\Delta S^0$ ) can be calculated. Now, the standard states of gelation process are taken to be the micelles in ideal dilute solution at unit molarity and micelles in gel state.

$$10 \quad c. \quad \Delta G^0 = RT_{gel} \ln C_m$$

$$d. \quad \Delta H^0 = R[d \ln C_m / d(1/T_{gel})]$$

$$e. \quad \Delta S^0 = (\Delta G^0 - \Delta H^0) / T_{gel}$$

15

$C_m$  is the concentration of micelles in mole  $L^{-1}$  that is calculated by assuming that the aggregation number per micelle is 40.  $T_{gel}$  is the sol-to-gel transition temperature.  $\Delta H^0$  calculated from the slope of  $\ln C_m$  versus  $1/T_{gel}$  (**Fig. 8**) is  $146 \text{ kJ mole}^{-1}$  (micelle) or  $\Delta H^0 = 3.65 \text{ kJ mole}^{-1}$  (chain). This value is similar to gelation of poloxamer 407 ( $\Delta H^0 = 1.5 \text{ kJ mole}^{-1}$  (chain)) and PEG-PLGA-PEG triblock copolymers ( $\Delta H^0 = 1.32 \text{ kJ mole}^{-1}$  (chain)). Gibbs free energy ( $\Delta G^0$ ) and entropy ( $\Delta S^0$ ) for the gelation of 22 wt. % PEG-g-PLGA aqueous solution with a  $T_{gel}$  of  $30^\circ \text{C}$  are  $-0.59 \text{ kJ mole}^{-1}$  and  $1.9 \text{ J mole}^{-1} \text{ K}^{-1}$ , respectively. This calculation leads to the conclusion that the entropy drives the gelation. The molecular origin of such an entropy-driven process has been suggested as hydrophobic interactions. Water molecules tend to surround the hydrophobic segment (PLGA) to decrease the free energy. Consequently, the entropy of water molecules decreases in the presence of hydrophobes. Therefore, the surface area of hydrophobic molecules is minimized in water. Such hydrophobic interactions increase with increasing temperature, and

30

change the molecular conformation of PEG-g-PLGA, thus might drive the gelation.

The  $^{13}\text{C}$ -NMR analysis of the polymers was conducted at different temperatures to elucidate the structure of the gel and mechanism of gel formation (**Fig. 9**). Spectra of polymers dissolved in water and chloroform were compared. The  $^{13}\text{C}$ -NMR spectra of a 22 wt. % PEG-g-PLGA in  $\text{D}_2\text{O}$  were obtained at 20 (sol state), 30 (just above sol-to-gel transition), 40 (gel state), and 50 °C (macrophase-separated state) by simply increasing the temperature around the probe without changing NMR parameters. The equilibration time at each temperature was 15 minutes. Chloroform ( $\text{CDCl}_3$ ) is a nonselective good solvent for both PEG and PLGA blocks while water ( $\text{D}_2\text{O}$ ) is a good solvent for PEG but is a poor solvent for PLGA. The sharp peaks of both PEG and PLGA in chloroform are compared with a collapsed peak of PLGA in water at first and second rows of  $^{13}\text{C}$ -NMR, indicating core (PLGA)-shell (PEG) structure of the polymer in water. The molecular motion of PEG in water is decreased due to anchoring effects by the hydrophobic PLGA segments compared with that in chloroform. This fact is reflected in a broadened peak of PEG in  $\text{D}_2\text{O}$  at 20° C. The change in molecular association at sol-to-gel transition involves the change in molecular motion of the polymers. The change in  $^{13}\text{C}$ -NMR with increasing temperature (20 °C – 50° C) shows such a change in microenvironment around the PEG and PLGA. The PEG peak (72 ppm) at a gel state (30° C) is broadened and decreased by half in height compared with a sol state (20° C), whereas there is a slight increase in PLGA peak height (20 ppm) at gel state (30° C). These changes in peak heights indicate a significant decrease in molecular motion of the PEG backbone, and increased thermal motions of the PLGA side chains during sol-to-gel transition. This behavior is quite different from that of PLGA-g-PEG. PLGA-g-PEG showed little change in PEG peak during sol-to-gel transition at the  $^{13}\text{C}$ -NMR in  $\text{D}_2\text{O}$ . Based on these observations, the following model can be suggested for the sol-to-gel transition of PEG-g-PLGA copolymer aqueous solutions. In



a sol state, the polymer conformation is micellar where the PEGs occupy shell and PLGAs occupy core of the micelle. The degree of association in a sol state is not enough to form a three dimensional network. With increasing temperature, the hydrophobic interactions increase and associations of polymers decrease the PEG molecular motion, resulting in a long-range network formation, that is, a gel. The degree of association is strong enough to keep its integrity in the presence of excess water at a given temperature such as 37° C. Therefore, we can define this system as a gel rather than a solution with an increased viscosity. As the temperature increases further, the long-range interactions among the polymers increase and phase mixing between PEG and PLGA occurs, resulting in the macrophase separation between water and polymer that occurs at 50° C.

The 22 wt.% polymer solutions (0.5 g) are injected into 4 mL vials (diameter of 1.1 cm) and kept in a 37° C water bath for five minutes. During this time the gel forms. 3 mL of phosphate buffer saline (37° C, pH=7.4) is added and the vials are shaken (16 strokes/minute) in the water bath to simulate body condition. The gel keeps its integrity for one-week *in vitro*, and the initially turbid gel becomes transparent in 3 to 7 days. After 7 days, the gel totally disintegrated to become a clear polymer solution.

This material can be applied for a short-term delivery of bioactive agents such as pharmaceutical drugs (e.g. proteins, anticancer drugs) as well as a carrier or delivery system for bioactive agents used in tissue engineering. The hydrophobicity of the drug and the molecular structure of the polymers affect the extent of diffusion or degradation dominant drug release profile. Therefore, by choosing the appropriate drug and molecular parameters of PEG-g-PLGA, a short-term delivery system can be designed based on this polymer hydrogel.

Synthesis: one step synthesis of PLGA-g-PEG

The graft copolymer PLGA-g-PEG was synthesized by a one-step ring opening polymerization of DL-lactide, glycolide, and epoxy terminated poly(ethylene glycol) (PEG; m.w.=600) using stannous octoate as a catalyst. The DL-lactic acid/glycolic acid/ethylene glycol mole ratio is 3.2/1/2.8, which was determined by H-NMR. Therefore, the grafting frequency of PEG is 4.7% by mole. Therefore, the grafting frequency of PEG is 4.7 % by mole. The weight average molecular weight ( $M_w$ ) and polydispersity ( $M_w/M_n$ ) of the polymers determined by gel permeation chromatography (GPC) relative to polystyrene standards using tetrahydrofuran as an eluting solvent, are 4200 and 1.3, respectively.

#### Sol-gel Transition:

At room temperature, viscosity of the 25 wt. % aqueous solutions is about 0.3 poise ( $\text{gm}^{-1}\text{s}^{-1}$ ), which allows for injecting the solution using a 25-gauge needle. With increasing temperature, the aqueous solutions (25 wt. %) of PLGA-g-PEG undergo a sol-to-gel transition at 30° C. The gel state is traditionally defined as a non-flowing semisolid by a test-tube inversion method. In the practical application, the gel should keep its equilibrium-swollen state and not dissolve in an excess amount of solvent. Further increase in temperature of the PLGA-g-PEG aqueous solution (25 wt. %) results in a macroscopic phase-separation between gel and water, that is, syneresis occurs at 50° C.

#### Dynamic Mechanical Analysis:

The sol-gel transition of the graft copolymer aqueous solution was investigated using dynamic rheometry (Rheometric Scientific: SR 2000) in a similar manner to poloxamer aqueous solutions. The polymer solution was placed between parallel plates having a diameter of 25 mm and a gap distance of 0.5 mm. The data were collected under controlled stress ( $4.0 \text{ dyne/cm}^2$ ) and a frequency of 1.0 radian/second. The heating and cooling rate was 0.2° C/min. By the dynamic mechanical

analysis, sol-gel transition can be identified in a more reproducible and quantitative manner than the test-tube inversion method.

The modulus of the PLGA-g-PEG aqueous solution is shown in Figure 10 as a function of temperature and concentration. The storage modulus increases abruptly at the sol-to gel transition. The gels have a modulus of about 50 dyne/cm<sup>2</sup> and are slightly affected by concentration in a range of 22 to 29 wt. %. The sol-to-gel transitions occur at around 30° C, suggesting easy formulation at room temperature.

To confirm the reversibility of the sol-gel transition, 25 wt. % PLGA-g-PEG aqueous solutions were studied. The real part ( $\eta'$ ) of complex viscosity of the polymer solution, which is a measure of dissipated energy when cyclic deformation is applied to a material, is shown as a function of temperature in Figure 11a. During the first heating cycle (H1),  $\eta'$  increased 1000 times upon sol-to-gel transition. The cooling curve (C1) shows that the gel phase persisted over the temperature range of 43 ~ 20 °C in the experimental time scale. This fact results from the difficulty in molecular rearrangement in the gel phase; once the solution forms a gel, the molecules resist disintegration.  $\eta'$  abruptly decreased at 15° C due to gel-to-sol transition during the cooling of the system. The second heating curve (H2) shows sol-to-gel transition at practically the same temperature as the first heating curve (H1).

The storage moduli ( $G'$ ) of the PLGA-g-PEG aqueous solutions (25 wt. %), which are a measure of stored energy when a cyclic deformation is applied to a material, are practically zero at a sol state and are not shown in the heating curve (Figure 11b; H1).  $G'$  sharply increased during sol-to-gel transition at 32° C as shown in heating curves. The maximum value for  $G'$  was measured between 35 ~ 39° C, indicating a promising material for *in-vivo* (37° C) applications. During the cooling cycle (C1), the gel modulus increased over the temperature range of 43 ~ 20° C, exhibiting similar behavior to typical elastic materials, and dropped abruptly at 15° C due to gel-to-sol transition. During the first (H1) and second (H2) heating cycle, practically the same transition curve was

measured for  $G'$ , indicating a reversible gelation. The decrease in  $G'$  at temperatures above 40 ~ 45° C can be expected due to increase in thermal motion. This trend was also observed with  $^{13}\text{C}$ -NMR spectra (Figure 12).

#### NMR Study:

The  $^{13}\text{C}$ -NMR spectra of a 25 wt. % copolymer solution in  $\text{D}_2\text{O}$  were recorded at different temperatures. In the sol state (20 °C), the methyl peak of the hydrophobic PLGA (18 ppm) is collapsed and broadened compared with PEG peak (72 ppm) whereas that in  $\text{CDCl}_3$  appears as a sharp peak, indicating core-shell structure of this polymer in water. The core-shell structure of these amphiphilic copolymers was also confirmed by micelle formation in diluted aqueous solutions. The critical micelle concentration (CMC) determined by a dye solubilization method was 0.03 wt. % at 20°C.

Just above the sol-to-gel transition temperature (33 °C) of an aqueous PLGA-g-PEG copolymer solution (25 wt. %), the  $^{13}\text{C}$ -NMR peak shapes of both the hydrophobic PLGA methyl peak and hydrophilic PEG peak are preserved except that the PEG peak was shifted down field about 0.3 ppm. With a further increase in temperature, the peak height of the PLGA methyl peak increases, and the PEG peak is split into two peaks, a sharp one at 72.4 ppm and a broad one at 72.7 ppm. These behaviors are thought to be caused by an increase in molecular motion of the hydrophobic backbone and phase mixing between PEG and PLGA. The phase mixing between PEG and PLGA or PLLA was previously reported. Further increase in temperature resulted in macrophase separation between water and the polymer.

The reversibility of the sol-gel transition is also confirmed by deuterium NMR (Figure 13). The peak at 4.8 ppm at 20 °C (sol state) shifted to 4.6 ppm at 33 °C (just above sol-to-gel transition), 4.58 ppm at 37° C (gel state), 4.56 ppm at 40 °C, and 4.5 ppm at 50° C (syneresis). The change in chemical shift was the most pronounced during the sol-to-

gel transition ( $\delta = 0.2$  ppm) and then during syneresis. When the system is cooled to 20°C, the deuterium peak reappears at 4.8 ppm, indicating the reversibility of the transition. In a sol state, water moves more freely than in a gel state. During the sol-to-gel transition, PEG becomes more hydrophobic due to dehydration and the extent of hydrogen bonding between water molecules and polymers changes. Therefore, the time average environment around deuterium nuclei will be affected, leading to the changes in chemical shift of water during sol-to-gel transition. This finding suggests that the deuterium NMR can be a good method for the determination of sol-gel transition.

The sol-to-gel transition temperature could be controlled from 20° to 40° C by changing PEG length and composition. When the PEG molecular weight of PLGA-g-PEG increases from 600 to 1000 the sol-to-gel transition occurred at 40° C, whereas the sol-to-gel transition occurred at 20° C when the PEG composition is decreased by 20 % in mole.

#### Varying gel durability:

The time frame for gel durability can be varied by adjusting the ratio of the two blocks in the formula  $A_n(B)$  (where  $n$  is  $>2$ ). To test and exemplify the duration of a gel 0.5 g of a polymer solution (see table below) was injected into a 4 ml vial (inner diameter 1.1 cm) and maintaining at 37° C for 5 minutes to allow the gel to form. After the gel is formed, 3 ml of phosphate buffer saline (37° C, pH=7.4) is added and the vial is placed in a shaker bath (16 strokes/minute). The polymer was monitored daily for complete degradation and the top layer of the buffer was replaced at the time of monitoring. The following table shows the resulting gel durations for each ration of the polymer. PEG-g-PLGA had a molecular weight of 11,000 and PLGA-g-PEG had a molecule weight of 7,800.

Ratio (PEG-g-PLGA/PLGA-g-PEG)	100/0	60/40	50/50	40/60	0/100
Duration of a gel measured as described above.	1 day~1 week	3 days~2 weeks	2~4 weeks	3~6 weeks	6~10 weeks

### Conclusions

The aqueous solutions of PEG-g-PLGA copolymers exhibited sol-to-gel transition in response to an increase in temperature. Micelle formation was confirmed by Cryo-TEM and dye solubilization method. The micellar diameter was about 9 nm and CMC was in a range of 0.01-0.05 wt. %. <sup>13</sup>C-NMR shows that the molecular motion of PEG backbones decreases while that of PLGA side chains increases during sol-to-gel transition.

The 21-25 wt. % solutions exhibit low viscosity at room temperature and form gels at body temperature. The gel morphology changed from turbid to transparent, and the integrity of gel persisted for one week suggesting a promising candidate for short-term drug delivery systems.

The aqueous PLGA-g-PEG system showing a reversible sol-to-gel transition by increasing temperature was studied by dynamic mechanical analysis and NMR spectrophotometer. The rheological study of the copolymers in aqueous solution demonstrated that thermogelation occurred at about 30° C and the elastic gel modulus exhibited a maximum around body temperature (37° C). A preliminary *in vivo* study in a rat model confirmed *in situ* gel formation after subcutaneous injection of a 0.5 ml aqueous solution. The gel was still present at the injection site after 2 months. This fact clearly distinguishes this polymer from poly(ethylene glycol)-g-poly(DL-lactic acid-co-glycolic acid) PEG-g-PLGA copolymer hydrogels, which disintegrated in one week.

The system developed in this study is very promising for local delivery of bioactive agents such as proteins, anticancer drugs, and antiarthritis drugs by subcutaneous, intraperitoneal, ocular, vaginal or rectal administrations. Thermosensitivity enables the *in-situ* gel formation upon injection, therefore no surgical procedure is required to implant the drug delivery system and no organic solvent is needed for drug formulation. The physical properties of soft hydrogels reduce mechanical tissue irritation surrounding the injection site. Also, the polymers are biodegradable; therefore there is no need for surgical removal of the implant after the release of the pharmaceutical agent.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features herein before set forth and as follows in scope of the appended claim.

## CLAIMS

5 We claim:

1. A thermogelling biodegradable aqueous polymer solution,  
comprising:

- 10 a. a biodegradable polymer, comprising  
i.a polyethylene glycol (PEG) block, and  
ii.a biodegradable polyester block, wherein  
iii.said blocks are linked to form a polymer of a general  
structure comprising the formula of  $A_n(B)$ , where n is greater than 2 and  
15 A is selected from the group consisting of a polyethylene glycol block and  
a biodegradable polyester block, B is selected from the group consisting  
of a polyethylene glycol block and a biodegradable polyester block, and A  
is different from B; and  
b. an aqueous solution.

20

2. A thermogelling biodegradable aqueous polymer solution  
according to claim 1 wherein n is between 3 and 10.

3. A thermogelling biodegradable aqueous polymer solution  
25 according to claim 1 wherein said polyethylene glycol (PEG) has an  
average molecular weight of between about 300 and 20,000.

4. A thermogelling biodegradable aqueous polymer solution  
according to claim 1 wherein said polyethylene glycol (PEG) has an  
30 average molecular weight of between about 500 and 10,000.



5. A thermogelling biodegradable aqueous polymer solution according to claim 1 wherein said polyester block has an average molecular weight of between about 1,000 and 30,000.

6. A thermogelling biodegradable aqueous polymer solution according to claim 1 wherein said polyester block has an average molecular weight of between about 1,000 and 10,000.

7. A thermogelling biodegradable aqueous polymer solution according to claim 1, wherein said biodegradable polyester block is selected from the group consisting of poly(DL-lactic acid), poly(L-lactic acid), poly(glycolic acid), poly( $\epsilon$ -caprolactone), poly( $\gamma$ -butyrolactone), poly( $\gamma$ -valerolactone), poly( $\beta$ -hydroxybutyric acid), and their copolymers or terpolymers.

8. A thermogelling biodegradable aqueous polymer solution according to claim 7, wherein said copolymers and/or terpolymers are selected from the group consisting of poly(DL-lactic acid-co-glycolic acid), poly(L-lactic acid-co-glycolic acid), poly( $\epsilon$ -caprolactone-co-DL-lactic acid), copoly( $\epsilon$ -caprolactone-co-DL-lactic acid-glycolic acid).

9. A biodegradable bioactive agent delivery system, comprising:  
a. an effective amount of bioactive agent contained in;  
b. a thermogelling biodegradable aqueous polymer solution comprising

i. A biodegradable polymer, comprising a polyethylene glycol (PEG) block a biodegradable polyester block, wherein said blocks are linked to form a polymer of a general structure comprising the formula of  $A_n(B)$ , where  $n$  is greater than 2 and  $A$  is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block,  $B$  is selected from the group consisting of a polyethylene

glycol block and a biodegradable polyester block, and A is different from B, and

ii. an aqueous solution.

5           10. A biodegradable bioactive agent delivery system according to claim 9 wherein said bioactive agent is a drug.

          11. A biodegradable bioactive agent delivery system according to claim 10 wherein said drug is selected from the group consisting of anti-  
10 cancer agents, hormones, antibiotics, narcotic antagonists, analgesics, anti-inflammatory agents, anti-depressants, anti-epileptics, anti-malarial agents, immunoactivators, growth factors, radioprotection agents, vaccines, gene therapy agents, oligonucleotides, antisense, peptides and proteins, and combinations thereof.

15

          12. A biodegradable bioactive agent delivery system according to claim 10 wherein said drug is an anti-cancer agent.

          13. A biodegradable bioactive agent delivery system according to  
20 claim 12 wherein said anti-cancer agent is a member selected from the group consisting of adriamycin, mitomycin, bleomycin, cisplatin, carboplatin, doxorubicin, daunorubicin, 5-fluorouracil, methotrexate, taxol, taxotere, and actinomycin D.

25           14. A biodegradable bioactive agent delivery system according to claim 10 wherein said drug is a polypeptide.

          15. A biodegradable bioactive agent delivery system according to claim 14 wherein said polypeptide is a member selected from the group  
30 consisting of oxytocin, vasopressin, adrenocorticotrophic growth factor (PDGF), prolactin, luteinising hormone releasing hormone (LHRH), growth hormone, growth hormone releasing factor, insulin,

somatostatin, glucagons, interleukin 2 (IL 2), interferon- $\alpha,\beta,\gamma$  (IFN- $\alpha,\beta,\gamma$ ), gastrin, tetragastrin, pentagastrin, urogastroin, secretin, calcitonin, enkephalins, endorphins, angiotensins, thyrotropin releasing hormone (TRH), tumor necrosis factor (TNF), nerve growth factor (NGF), granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (M-CSF), rennin, bradykinin, bacitracins, alpha-1 antitrypsin, platelet derived growth factor, albumin, anti-thrombin III, glucocerebrosidase, DNase, tissue plasminogen activator, calcitonin, clotting factors VII, VIII, and IX, LHRH antagonists, insulin, erythropoietin, polymyxins, colistins, tyrocidin, gramicidines, and synthetic analogues, modifications and pharmacologically active fragments thereof, monoclonal antibodies and soluble vaccines.

16. A biodegradable bioactive agent delivery system according to claim 9 wherein said therapeutic agent is a cell.

17. A biodegradable bioactive agent delivery system according to claim 9 wherein said thermogelling biodegradable aqueous polymer solution provides as a solubilizer.

20

18. A method for the parenteral delivery of a bioactive agent in a thermogelling polymer matrix to a warm blooded animal for the controlled release of said bioactive agent, which comprises:

a. providing an injectable thermogelling biodegradable aqueous polymer solution, which comprises

i. A biodegradable polymer, comprising a polyethylene glycol (PEG) block, a biodegradable polyester block, wherein said blocks are linked to form a polymer of a general structure comprising the formula of  $A_n(B)$ , where n is greater than 2 and A is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block, B is selected from the group consisting of a polyethylene

30

glycol block and a biodegradable polyester block, and A is different than B, and

ii. an aqueous solution;

b. mixing said thermogelling biodegradable aqueous

5 polymer solution with an effective amount of bioactive agent to form a polymer-bioactive agent mixture;

c. maintaining said polymer-bioactive agent mixture at a temperature below the gelling temperature of said polymer; and

d. injecting said solution parenterally into said warm  
10 blooded animal forming a gel depot of said bioactive agent and biodegradable polymer as the temperature of the solution is raised by the body temperature of said animal to be above the gelling temperature of said polymer.

15 19. A method according to claim 18 wherein said bioactive agent is a drug.

20 20. A method according to claim 19 wherein said drug is an anti-cancer agent.

21. A method according to claim 20 wherein said anti-cancer agent is a member selected from the group consisting of adriamycin, mitomycin, bleomycin, cisplatin, carboplatin, doxorubicin, daunorubicin, 5-fluorouracil, methotrexate, taxol, taxotere, and actinomycin D.

25 22. A method according to claim 19 wherein said drug is a polypeptide.

30 23. A method according to claim 22 wherein said polypeptide is a member selected from the group consisting of oxytocin, vasopressin, adrenocorticotrophic growth factor (PDGF), prolactin, luteinising hormone releasing hormone (LHRH), growth hormone, growth

hormone releasing factor, insulin, somatostatin, glucagons, interleukin-2 (IL-2), interferon- $\alpha, \beta, \gamma$  (IFN- $\alpha, \beta, \gamma$ ), gastrin, tetragastrin, pentagastrin, urogastroine, secretin, calcitonin, enkephalins, endorphins, angiotensins, thyrotropin releasing hormone (TRH), tumor necrosis factor (TNF), nerve growth factor (NGF), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (M-CSF), rennin, bradykinin, bacitracins, alpha-1 antitrypsin, platelet derived growth factor, albumin, anti-thrombin III, glucocerebrosidase, DNase, tissue plasminogen activator, calcitonin, clotting factors VII, VIII, and IX, LHRH antagonists, insulin, erythropoietin, polymixins, colistins, tyrocidin, gramicidines, and synthetic analogues, modifications and pharmacologically active fragments thereof, monoclonal antibodies and soluble vaccines.

24. A method for the delivery of a bioactive agent in a thermogelling polymer matrix to a warm blooded animal for the controlled release of said bioactive agent, which comprises:
- a. providing a thermogelling biodegradable aqueous polymer solution, which comprises
    - i. A biodegradable polymer, comprising a polyethylene glycol (PEG) block, a biodegradable polyester block, wherein said blocks are linked to form a polymer of a general structure comprising the formula of  $A_n(B)$ , where  $n$  is greater than 2 and  $A$  is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block,  $B$  is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block, and  $A$  is different than  $B$ , and
    - ii. an aqueous solution;
  - b. mixing said thermogelling biodegradable aqueous polymer solution with an effective amount of bioactive agent to form a polymer-bioactive agent mixture;

c. maintaining said polymer-bioactive agent mixture at a temperature below the gelling temperature of said polymer; and

d. providing said polymer-bioactive agent mixture into said warm blooded animal forming a gel depot of said bioactive agent and biodegradable polymer as the temperature of the liquid is raised by the body temperature of said animal to be above the gelling temperature of said polymer.

25. A method according to claim 24 wherein said bioactive agent is a drug.

26. A method according to claim 25 wherein said drug is selected from the group consisting of anti-cancer agents, hormones, antibiotics, narcotic antagonists, analgesics, anti-inflammatory agents, anti-depressants, anti-epileptics, anti-malarial agents, immunoactivators, growth factors, radioprotection agents, vaccines, gene therapy agents, oligonucleotides, antisense, peptides and proteins, and combinations thereof.

27. A method according to claim 25 wherein said drug is an anti-cancer agent.

28. A method according to claim 27 wherein said anti-cancer agent is a member selected from the group consisting of adriamycin, mitomycin, bleomycin, cisplatin, carboplatin, doxorubicin, daunorubicin, 5-fluorouracil, methotrexate, taxol, taxotere, and actinomycin D.


29. A method according to claim 25 wherein said drug is a polypeptide.

30. A method according to claim 29 wherein said polypeptide is a member selected from the group consisting of oxytocin, vasopressin,

adrenocorticotrophic growth factor (PDGF), prolactin, luteinising hormone releasing hormone (LHRH), growth hormone, growth hormone releasing factor, insulin, somatostatin, glucagons, interleukin 2 (IL-2), interferon- $\alpha, \beta, \gamma$  (IFN-  $\alpha, \beta, \gamma$ ), gastrin, tetragastrin, pentagastrin, urogastroine, secretin, calcitonin, enkephalins, endorphins, angiotensins, thyrotropin releasing hormone (TRH), tumor necrosis factor (TNF), nerve growth factor (NGF), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (M-CSF), rennin, bradykinin, bacitracins, alpha-1 antitrypsin, platelet derived growth factor, albumin, anti-thrombin III, glucocerebrosidase, DNase, tissue plasminogen activator, calcitonin, clotting factors VII, VIII, and IX, LHRH antagonists, insulin, erythropoietin, polymyxins, colistins, tyrocidin, gramicidines, and synthetic analogues, modifications and pharmacologically active fragments thereof, monoclonal antibodies and soluble vaccines


31. A biodegradable polymer, comprising:
- a polyethylene glycol (PEG) block; and
  - a biodegradable polyester block, wherein;
  - said blocks are linked to form a polymer of a general structure comprising the formula of  $A_n(B)$ , where n is greater than 2 and A is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block, B is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block, and A is different from B.

1/12


*Fig. 1*



2/12



3/12

*Fig. 3*

4/12








Fig. 4


5/12

*Fig. 5a**Fig. 5b*


6/12

*Fig. 6*


7/12

*Fig. 8*

8/12



*Fig 9*

9/12


*Fig. 10*




10/12

*Fig. 11a*

11/12

*Fig. 12*

12/12

*Fig. 13*

The first part of the document discusses the importance of maintaining accurate records of all transactions. It emphasizes that proper record-keeping is essential for the integrity of the financial system and for the ability to detect and prevent fraud. The document then outlines the specific requirements for record-keeping, including the need to maintain separate accounts for each transaction and to ensure that all records are properly indexed and filed.

The second part of the document discusses the importance of maintaining accurate records of all transactions. It emphasizes that proper record-keeping is essential for the integrity of the financial system and for the ability to detect and prevent fraud. The document then outlines the specific requirements for record-keeping, including the need to maintain separate accounts for each transaction and to ensure that all records are properly indexed and filed.

The third part of the document discusses the importance of maintaining accurate records of all transactions. It emphasizes that proper record-keeping is essential for the integrity of the financial system and for the ability to detect and prevent fraud. The document then outlines the specific requirements for record-keeping, including the need to maintain separate accounts for each transaction and to ensure that all records are properly indexed and filed.

The fourth part of the document discusses the importance of maintaining accurate records of all transactions. It emphasizes that proper record-keeping is essential for the integrity of the financial system and for the ability to detect and prevent fraud. The document then outlines the specific requirements for record-keeping, including the need to maintain separate accounts for each transaction and to ensure that all records are properly indexed and filed.

The fifth part of the document discusses the importance of maintaining accurate records of all transactions. It emphasizes that proper record-keeping is essential for the integrity of the financial system and for the ability to detect and prevent fraud. The document then outlines the specific requirements for record-keeping, including the need to maintain separate accounts for each transaction and to ensure that all records are properly indexed and filed.

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
4 April 2002 (04.04.2002)

PCT

(10) International Publication Number  
WO 02/026215 A3(51) International Patent Classification : A61K 9/51  
C08L 67/02, A61K 9/00, 47/34(72) Inventors: JEONG, Byeong, Moon, 2651 Sandstone  
Lane, Richland, WA 99352 (US); GUTOWSKA, Anna,  
450 Mateo Court, Richland, WA 99352 (US)

(21) International Application Number: PCT/US01/30322

(22) International Filing Date:  
27 September 2001 (27.09.2001)


(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/236,926 28 September 2000 (28.09.2000) US  
09/833,460 11 April 2001 (11.04.2001) US(71) Applicant: BATTELLE MEMORIAL INSTITUTE  
[US/US]; Pacific Northwest Division, Intellectual Property  
Services, P.O. Box 999, Richland, WA 99352 (US)(74) Agent: MAY, Stephen, R., Battelle Memorial Institute,  
Pacific Northwest Division, Intellectual Property Services,  
P.O. Box 999, MSIN K1 53, Richland, WA 99352 (US)(81) Designated States (national): AE, AG, AI, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

[Continued on next page]

(54) Title: THERMOGELLING BIODEGRADABLE AQUEOUS POLYMER SOLUTION



(57) Abstract: Disclosed is a thermogelling biodegradable aqueous polymer solution useful in providing a bioactive agent delivery system. The present invention provides a thermogelling biodegradable aqueous polymer solution with a polyethylene glycol (PEG) block and a biodegradable polyester block, where the blocks are linked to form a polymer of a general structure comprising the formula of  $A_n(B)_m$ , where  $n$  is greater than 2 and  $A$  is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block,  $B$  is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block, and  $A$  is different from  $B$ .

WO 02/026215 A3



EE, EU, MC, NE, PE, SE, TR) OAPI patent (BE, BF, CI, CG, CL, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

(88) Date of publication of the international search report:  
30 January 2003

**Published:**  
*with international search report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette*

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 01/30322

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K 9/53 COM 67/02 A61K9/00 A61K47/34

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbol)

IPC 7 A61K COM 67/02

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 55147 A (BATTELLE MEMORIAL INSTITUTE) 10 December 1998 (1998-12-10) claims	1-31
A	US 5 702 717 A (Y. CHA ET AL.) 30 December 1997 (1997-12-30) cited in the application claims	1-31
A	US 6 117 949 A (R.C.RATHI ET AL.) 12 September 2000 (2000-09-12) cited in the application claims	1-31
A	US 4 526 938 A (J.R.CHURCHILL ET AL.) 2 July 1985 (1985-07-02) claims	1-31

☐ Further documents are listed in the continuation of box C☒ Patent family members are listed in annex

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*I\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*I\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*S\* document member of the same patent family

Date of the actual completion of the international search

28 August 2002

Date of mailing of the international search report

05/09/2002

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/30322

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos. :  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 18-30 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos. :  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos. :  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



## INTERNATIONAL SEARCH REPORT

Information on patent family members:

International Application No.

PCT/US 01/30322

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9855147	A	10-12-1998	EP 0986402 A2	22-03-2000
			JP 2001508802 T	03-07-2001
			WO 9855147 A2	10-12-1998
US 5702717	A	30-12-1997	AU 7520096 A	15-05-1997
			EP 0863745 A1	16-09-1998
			JP 11513985 T	30-11-1999
			WO 9715287 A1	01-05-1997
			ZA 9608944 A	21-07-1997
US 6117949	A	12-09-2000	AU 1098300 A	17-04-2000
			AU 736812 B2	02-08-2001
			AU 9678093 A	27-04-1999
			BR 9815239 A	11-12-2001
			BR 9914253 A	03-07-2001
			CA 2305621 A1	15-04-1999
			CN 1282345 T	31-01-2001
			CN 1324374 T	28-11-2001
			EP 1034207 A1	13-09-2000
			FP 1141079 A1	10-10-2001
			JP 2002516910 T	11-06-2002
			NO 20011639 A	30-03-2001
			PL 346963 A1	11-03-2002
			TR 200000900 T2	21-08-2000
			TR 200100900 T2	22-10-2001
			WO 9918142 A1	15-04-1999
			WO 0018821 A1	06-04-2000
			US 6201072 B1	13-03-2001
US 4526938	A	02-07-1985	AT 37983 T	15-11-1988
			AU 566010 B2	08-10-1987
			AU 1328083 A	27-10-1983
			CA 1246265 A1	06-12-1988
			DE 3378250 D1	24-11-1988
			DK 178583 A ,B,	23-10-1983
			EP 0092918 A2	02-11-1983
			ES 521713 D0	01-12-1984
			ES 8501779 A1	01-03-1985
			ES 535112 D0	01-12-1985
			ES 8602858 A1	16-03-1986
			FI 831368 A ,B,	23-10-1983
			GR 78529 A1	27-09-1984
			HU 198093 B	28-07-1989
			IE 54728 B1	17-01-1990
			IL 68426 A	31-08-1986
			JP 2090490 C	18-09-1996
			JP 4210928 A	03-08-1992
			JP 7088312 B	27-09-1995
			JP 1823155 C	10-02-1994
			JP 5017245 B	08-03-1993
			JP 58191714 A	09-11-1983
			NO 831413 A ,B	24-10-1983
			NO 841544 A	24-10-1983
			NO 164302 B	11-06-1990
			NZ 203970 A	11-04-1986

# INTERNATIONAL SEARCH REPORT

Information on patent family member:

International Application No.

PC1/US 01/30322

Parent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4526938	A	ZA 8302601 A	29-02-1984

Form PCT/ISA/210 (patent family annex) (July 1992)